dr. maughan discusses abiraterone plus olaparib in mcrpc
Published 6 years ago • 230 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
4:30
profound: olaparib for hrr mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
3:55
abiraterone plus prednisone in crpc: factors to consider
-
2:09
dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
1:15
magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
-
8:09
treating mcrpc with newer hormonal agents
-
2:10
dr. gulley discusses a phase ii study of olaparib and durvalumab in mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
1:30
dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc
-
2:20
mcrpc case impressions & adt abiraterone response